Tonix Pharmaceuticals Holdings Corp (NASDAQ:TNXP) is up 58% this year. In addition, the company announced that it had been added the small-cap Russell 2000 and Russell 3000 Indexes effective June 28, 2021. The addition is part of the Russell stock indexes’ annual reconstitution.Seth Lederman, Tonix CEO, said they are delighted to be part of the Russell indexes, reflecting the country’s growth and achievements over the past year. Lederman said that they are looking forward to enhanced awareness of the company following the inclusion.
Recently the company announced plans to develop TNX-102 SL as a potential Long COVID syndrome treatment. The company will meet the FDA in Q3 2021 to discuss potential phase 2 study design and clinical development plan qualifying TNX-102 SL as a Long COVID treatment.
Lederman said they are delighted to commence the development of TNX-102 SL as a Long COVID treatment. He said that the program leverages what Tonix has learned about TNX-102 SL’s pharmacodynamics activity. in the coming months, TNXP is a stock to watch.
Market Reaction:
On Tuesday, TNXP stock fell 5.80% to $1.14 with more than 12.12 million shares, compared to its average volume of 11.23 million shares. The stock has moved within a range of $1.1300 – 1.2100 after opening the trade at $1.21. Over the past 52-week, the stock has been trading within a range of $0.5100 – 2.4600.
 Stock Up 58% YTD: But Why?){kind=link}